COMMUNIQUÉS West-GlobeNewswire

Greenwich LifeSciences Provides Update on Financing Strategy
14/04/2026
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14/04/2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
14/04/2026
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics Forum (April 27) [...]
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
14/04/2026
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026 QUVIVIQ® is approved through Taiwan’s Streamlined Review [...]
Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
14/04/2026
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling access to accelerated and rolling review FDA clearance of IND [...]
Transactions in connection with share buy-back program
14/04/2026
Company announcement no. 10 - 26 14 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
PannTheraPi Announces Significant Clinical Development and Strategic Milestones
14/04/2026
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and severe form of epilepsy PannTheraPi secures European patent covering [...]
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique
14/04/2026
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat médicament, PTI5803, [...]
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
14/04/2026
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare Novo Nordisk will integrate OpenAI's most advanced AI capabilities globally [...]
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
14/04/2026
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized [...]
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
14/04/2026
MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors CAMBRIDGE, United Kingdom, April 14, 2026 (GLOBE [...]
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
14/04/2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% [...]
Rapid Nutrition Strengthens Capital Markets Infrastructure with Appointment of Bowsprit Partners
14/04/2026
LONDON, April 13, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech and wellness company focused on evidence-based nutrition brands and technology-enabled wellness solutions, is [...]
Elite Force XL Male Enhancement Gummies Claims Evaluated: Effective Men's Formula for Steel Power Support
14/04/2026
A 2026 informational overview of Elite Force XL's male performance gummy formula, testosterone support positioning, ingredient category context, and what men seeking steel power should verify before purchasing New York [...]
GloraMD Face Lift Serum Claims Evaluated: Liquid Anti-Aging Wrinkle Serum Solution for Skin Renewal
14/04/2026
A GloraMD Product Overview: Peptide Ingredients, Wrinkle Reduction Positioning, Anti-Aging Serum Formula Details, and Consumer Information for 2026 Los Angeles, April 13, 2026 (GLOBE NEWSWIRE) -- Affiliate Disclosure: [...]
Vital Step GLP-1 Claims Evaluated: Trusted Doctor-Prescribed GLP-1 Weight Loss Medication with No Hidden Fees
14/04/2026
A 2026 program overview covering how Vital Step structures its doctor-prescribed compounded semaglutide and tirzepatide programs, monthly pricing, prescription access, and what adults considering medically supervised [...]
Clean Eye Claims Evaluated: The CleanEye Vision Care Capsules for Retina Clear Visual Support
14/04/2026
A 2026 Informational Overview of CleanEye Vision Care Capsules, Retina Support Ingredient Categories, Lutein and Zeaxanthin Research Context, and Label Transparency for Eye Wellness Supplements Largo, FL, April 13, 2026 [...]
AIM ImmunoTech Provides Routine Update on Annual Filings
14/04/2026
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year ended December 31, [...]
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
13/04/2026
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its intention [...]

Pages